Pten Dose Dictates Cancer Progression in the Prostate
Kettering University · Memorial Sloan Kettering Cancer Center · +3 more institutions
Abstract
Complete inactivation of the PTEN tumor suppressor gene is extremely common in advanced cancer, including prostate cancer (CaP). However, one PTEN allele is already lost in the vast majority of CaPs at presentation. To determine the consequence of PTEN dose variations on cancer progression, we have generated by homologous recombination a hypomorphic Pten mouse mutant series with decreasing Pten activity: Pten(hy/+) > Pten(+/-) > Pten(hy/-) (mutants in which we have rescued the embryonic lethality due to complete Pten inactivation) > Pten prostate conditional knockout (Pten(pc)) mutants. In addition, we have generated and comparatively analyzed two distinct Pten(pc) mutants in which Pten is inactivated focally…
Citation impact
- FWCI
- 8.82
- Percentile
- 100%
- References
- 37
Authors
12- LCLloyd C. Trotman
Kettering University, Memorial Sloan Kettering Cancer Center
- MNMasaru Niki
Memorial Sloan Kettering Cancer Center, Kettering University
- ZDZohar Dotan
Kettering University, Memorial Sloan Kettering Cancer Center
- JAJason A. Koutcher
Kettering University, Memorial Sloan Kettering Cancer Center
- ADAntonio Di Cristofano
Kettering University, Memorial Sloan Kettering Cancer Center
Topics & keywords
- PTEN
- Biology
- Cancer research
- Prostate cancer
- Haploinsufficiency
- PI3K/AKT/mTOR pathway
- Cancer
- Tumor suppressor gene
- Good health and well-being